What percentage of HLA (Human Leukocyte Antigen) B27 positive individuals develop spondyloarthropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HLA-B27 and Spondyloarthropathy Development

Approximately 25% of HLA-B27 positive individuals will develop spondyloarthropathy over their lifetime, based on the most robust long-term cohort data available. 1

Key Epidemiologic Data

The most definitive evidence comes from a 35-year prospective follow-up study of first-degree relatives, which demonstrated that approximately 25% of HLA-B27 positive first-degree relatives developed axial spondyloarthropathy, regardless of whether their proband had radiographic sacroiliitis. 1 In stark contrast, only 3% of HLA-B27 negative first-degree relatives developed the disease. 1

Risk Stratification

The relative risk of developing spondyloarthropathy in HLA-B27 positive individuals is approximately 20-fold higher compared to HLA-B27 negative individuals. 2 This translates to:

  • HLA-B27 positive individuals: 13.6% prevalence of spondyloarthropathy in cross-sectional screening studies 2
  • HLA-B27 negative individuals: 0.7% prevalence 2

The calculated relative risk is 20.7 (95% CI: 4.6-94.2, p=0.001). 2

Clinical Context and Predictive Value

Among HLA-B27 positive individuals presenting with inflammatory back pain, approximately 50% will have sacroiliitis on imaging. 2 This substantially higher pretest probability makes HLA-B27 testing clinically useful when inflammatory back pain is already present, though the test alone is insufficient for diagnosis. 1

Important Caveats

  • HLA-B27 positivity varies by ethnicity, with lower frequencies reported in Asian Indian populations (56% in spondyloarthropathy patients versus 76% in Caucasian populations with ankylosing spondylitis). 3

  • The majority of HLA-B27 positive individuals (approximately 75%) will never develop spondyloarthropathy, which is why HLA-B27 testing is not recommended as a standalone screening tool in the general population. 1

  • HLA-B27 carriage does not adversely impact survival in individuals who do not develop spondyloarthropathy, providing reassurance to those who test positive during diagnostic evaluation but remain disease-free. 1

Predictive Features Beyond HLA-B27

Acute anterior uveitis significantly increases the likelihood of developing axial spondyloarthropathy in HLA-B27 positive individuals (odds ratio: 4.7,95% CI: 2.2-10.5). 1 Conversely, chronic inflammatory back pain at a young age was not a reliable predictor of long-term disease development. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.